Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 273
A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future DirectionsEvan S. Dellon, Seema S. Aceves, Gary W. Falk et al.|Gastroenterology|2022Cited by 109
Gastroenterological EndoscopyMeinhard Classen, Keiichi Ikeda, Guido N.J. Tytgat et al.|Unknown|2010Cited by 102
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Christine Lee et al.|Drugs|2022Cited by 6